AstraZeneca Leans Into In-House AI for Oncology Research Acceleration
Analysis
Key Takeaways
- •AstraZeneca is investing in in-house AI capabilities.
- •The focus is on integrating AI into research and clinical workflows.
- •The goal is to accelerate oncology drug development.
“The challenge is no longer whether AI can help, but how tightly it needs to be built into research and clinical work to improve decisions around trials and treatment.”